Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27663599.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Higher plasma concentrations of tyrosine kinase inhibitors (TKI), such as pazopanib, are associated with improved clinical outcomes. However, TKI pharmacokinetics exhibit significant interpatient variability, resulting in inconsistent and unpredictable plasma drug levels. An individualized dosing approach based on patient pharmacokinetics data and toxicity can potentially optimize plasma concentrations of pazopanib. Clin Cancer Res; 22(23); 5626-8. ©2016 AACRSee related article by Verheijen et al., p. 5738.
Medical subject headings
- Pharmaceutical Preparations
- Protein Kinase Inhibitors